Dual-center experiences with interventional closure of patent foramen ovale: A medium-term follow-up study comparing two patient groups aged under and over 60 years

Dejan Nachoski1 | Joerg Schroeder2 | Mohammad Almalla2 | Ralf Kubini1 | Vadim Tchaikovski1 | Christoph Kosinski3 | Michael Becker1 | Ali Aljalloud1,4

1Rhein-Maas Hospital, Department of Cardiology, Nephrology and Internal Intensive Care, Würselen, Germany
2RWTH University Hospital Aachen, Department of Cardiology, Pulmonology and Internal Intensive Care, Aachen, Germany
3Rhein-Maas Hospital, Department of Neurology, Würselen, Germany
4RWTH University Hospital Aachen, Department of Cardiac Surgery, Aachen, Germany

Correspondence
Prof. Michael Becker, MD, Department of Cardiology, Nephrology and Internal Intensive Care, Rhein-Maas Hospital, Mauerfeldchen 25, 52146 Würselen, Germany.
Email: michael.becker@rheinmaasklinikum.de

Abstract
Background: Current guidelines recommend interventional closure of patent foramen ovale (PFO) in patients with cryptogenic ischemic stroke who are under 60 years of age.
Hypothesis: The hypothesis of this study was to compare follow-up results of PFO closure in patients over 60 years of age to those of patients under 60 years of age in order to determine whether the procedure is safe and effective for both age groups.
Methods: We included 293 patients who had a cryptogenic ischemic stroke and a PFO confirmed by transesophageal echocardiography (TEE) and who were scheduled for percutaneous closure of the PFO between 2014 and 2019. The device implantation was completed in all patients using an Amplatzer™, Occlutech™, or Cardia Ultrascan PFO occluder.
Results: Follow-up TEE examinations were performed at intervals of 1, 3, and 6 months after implantation. Patients were followed for a median of 3.6 ± 1.2 years. Recurrent ischemic stroke or transient ischemic attack, cardiac death, arrhythmias, and residual shunt were reported equally in both groups.
Conclusions: Intervventional closure of PFO can be as safe and effective in patients over 60 years of age as it is in patients under 60 years of age regardless of the device used. In this older patient group, rigorous discussion and a case-by-case decision-making process including cardiologists and neurologists is warranted to ensure optimal procedure selection.

Keywords
cryptogenic stroke, elder patients, patent foramen ovale, PFO and atrial fibrillation, PFO closure

1 | INTRODUCTION

Even after in-depth and extensive investigation, the cause of more than 30% of strokes remains unknown.1,2 Patent foramen ovale (PFO) is quite controversially discussed in academic literature as a potential cause of cryptogenic stroke and has been reported to be found in 25% to 40% of the population.3

Several early studies asserted that a PFO does not necessarily increase the risk of stroke recurrence.4-6 Moreover, various researchers using metanalysis failed to find definitive proof that PFO closure reduced the risk of a recurrent stroke.7-10
However, the latest trials conducted with long-term follow-up of patients who received PFO closure successfully prove a significant reduction in the recurrence of cryptogenic stroke in patients under 60 years of age. Following these results, guidelines of the German Societies of Cardiology and Neurology strongly recommended interventional closure for these patients. Furthermore, additional studies report a strong association between the presence of a PFO and cryptogenic stroke. Thus, paradoxical embolism through a PFO may be an important cause of otherwise unexplained ischemic cerebral events. Current literature and studies covering the subject matter often fail to include elderly patients. Theoretically, patients face increasingly competing sources for embolic stroke with increasing age such as rhythm disturbances like atrial fibrillation or severe cerebrovascular disease.

The role of PFO closure in preventing stroke recurrence in patients older than 60 years remains uncertain particularly after exclusion of these concurrent pathways. PFO is still a potential cause of cryptogenic stroke in both older and younger populations. Thus, the present dual-center study was undertaken to retrospectively evaluate the medium-term clinical results after percutaneous closure using three well-established occlusion devices in older patients.

2 | METHODS

2.1 | Patient population

This study was approved by the local ethical committee. From 2014 to 2019, 293 consecutive patients with a PFO, at least one documented presumed paradoxical thromboembolic event and a scheduled percutaneous closure of the PFO defect were considered for this study. Patients were divided into two groups: patients under 60 years in age (Group A) and patients over 60 years in age (Group B) and signed informed consent forms. All data were analyzed retrospectively. An ischemic stroke was defined as an acute focal neurologic deficit, presumably due to ischemia, that either resulted in clinical symptoms lasting 24 hours or more or was associated with evidence of relevant infarction on magnetic resonance imaging (MRI) or, if MRI could not be performed, by computed tomography (CT) of the brain. All evidence was confirmed by a neurologist where the symptomatic patient first presented. In all cases, a PFO was identified by transesophageal echocardiography (TEE) and other thromboembolic risk factors were excluded, such as, (a) large vessel arteriopathy, (b) an intracardiac thrombus, masses and valve vegetations, (c) intrinsic small vessel disease, (d) cardiac arrhythmias (through 3-day electrocardiography), and (e) a hypercoagulable state (protein C and S, antithrombin III, antiphospholipid antibodies, and activated protein C resistance).

Post-intervention bleeding was defined as a decrease of hemoglobin count ≥ 2 g/dL.

2.2 | Echocardiography

TEE (iE33, Philips or E90, GE) was performed within 3 ± 2 weeks prior to device implantation (baseline) and at 3-months and 6-months follow-up. Atrial septal aneurysm (ASA) was diagnosed on the basis of a septum primum excursion greater than 10 mm as identified on transesophageal echocardiography. Shunts were defined by the appearance of microbubbles in the left atrium within three cardiac cycles after opacification of the right atrium at rest or during Valsalva maneuver. The degree of shunt was graded into three groups: 1–9 bubbles as “small,” up to 30 bubbles as “moderate,” and more than 30 bubbles as “large”. The results of PFO closure were assessed with the use of contrast echocardiography. Furthermore, device position and absence of thrombotic formations were evaluated.

2.3 | Implantation procedure

All patients received 100 mg of aspirin and 75 mg of clopidogrel daily for at least 1 week prior to intervention. In brief, venous access was gained through the right femoral vein under local anesthesia and device implantation was guided by fluoroscopy and TEE. The type and size of device was chosen by the physician performing the implantation according to (a) the diameter of the defect, (b) presence of an ASA, (c) availability of the device, and (d) appropriate preference. A randomization algorithm was not used.

2.4 | Post-implantation treatment

After implantation, patients continued to receive 100 mg of aspirin and 75 mg of clopidogrel daily for 3 months, followed by aspirin monotherapy for up to 6 months. Before hospital discharge, a transthoracic echocardiography was performed to confirm correct device position. Prophylaxis of infectious endocarditis was performed for the first 6 months. Clinical follow-ups were performed after 3 and 6 months by TEE. Additionally, telephone contact based on a centrally recorded database was conducted on an annual basis. All verification of database recordings and interviews was performed by an experienced nurse or physician. During this interview, the patient or a family member was queried for the occurrence of cardiac events, such as, (a) cardiovascular death, defined as any death with a demonstrable cardiovascular cause or any death that was not clearly attributable to a non-cardiovascular cause or (b) hospitalization for recurrent neurological or peripheral thromboembolic events. If such an event was identified, the referring general practitioner was contacted for detailed information. No loss of follow-up occurred. The mean follow-up period was 3.6 ± 1.2 years, the median monitoring interval was 3.2 years.

2.5 | Statistics

Continuous data are expressed as mean values ± SD and compared using Student’s t test or ANOVA as appropriate. Ordinal data were compared using the chi-square test. A p-value of <.05 was considered statistically significant. Analysis was conducted using SAS.
**3 | RESULTS**

**3.1 | Patient population**

The patient population included 293 consecutive symptomatic patients with scheduled percutaneous PFO closure procedures: 192 patients in Group A (mean age 47 ± 6 years) and 101 patients in Group B (mean age 67 ± 4 years). In all patients, Amplatzer™ (Group A, n = 53 patients, Group B, n = 11 patients), Cardia Ultrasept PFO (Group A, n = 95 patients, Group B, n = 77 patients), or Occlutech™ (Group A, n = 44 patients, Group B, n = 13 patients) occluders were implanted. Baseline characteristics are given in Table 1. The demographic and clinical characteristics of the two groups were generally well balanced (Table 1).

**3.2 | Implantation procedure and complication**

In the 293 study patients, device implantation failed in none (0) of the patients. Mean procedural time was 29 ± 6 minutes with a mean fluoroscopy time of 2 ± 1 minutes. The number of periprocedural complications was 8 (4%) in Group A and 5 (5%) in Group B with no significant differences between these groups (p = 0.772), see Table 2. One patient in Group A suffered from a severe air embolism, most likely due to a damaged delivery system, with need for hyperbaric oxygen therapy.

**3.3 | Endpoints during follow-up period**

Two patients in Group B were lost due to non-cardiac death (breast cancer, N = 1 and thrombotic thrombocytopenic purpura, N = 1).

---

**Table 1** Baseline of all included patients

| Group A | Amplatzer™ devices (N = 53) | Cardia Ultrasept PFO devices (N = 95) | Occlutech™ devices (N = 44) | p |
|---------|-----------------------------|----------------------------------------|----------------------------|---|
| Age, years | 46 ± 6 | 48 ± 7 | 47 ± 7 | 0.291 |
| Male sex, n (%) | 29 (54) | 48 (51) | 24 (55) | 0.493 |
| Medical history, n (%) | | | | |
| Diabetes mellitus | 3 (5) | 4 (4) | 5 (11) | 0.061 |
| Arterial hypertension | 15 (29) | 22 (23) | 9 (22) | 0.243 |
| Smoking | 12 (22) | 27 (29) | 14 (31) | 0.149 |
| Hypercholesterolemia | 12 (22) | 25 (26) | 12 (27) | 0.477 |
| Coronary artery disease | 1 (1) | 1 (1) | 0 (0) | 0.832 |
| Congestive heart failure | 1 (1) | 0 (0) | 0 (0) | 0.882 |
| Atrial septal aneurysm, n (%) | 19 (36) | 33 (35) | 14 (33) | 0.558 |
| Size of shunt by microbubbles | | | | |
| Small, n (%) | 9 (17) | 23 (24) | 7 (15) | 0.244 |
| Moderate, n (%) | 20 (38) | 29 (31) | 17 (39) | 0.342 |
| Large, n (%) | 24 (45) | 43 (45) | 20 (46) | 0.638 |

| Group B | Amplatzer™ devices (N = 11) | Cardia Ultrasept PFO devices (N = 77) | Occlutech™ devices (N = 13) | p |
|---------|-----------------------------|----------------------------------------|----------------------------|---|
| Age, years | 68 ± 3 | 65 ± 4 | 67 ± 4 | 0.332 |
| Male sex, n (%) | 5 (48) | 42 (55) | 7 (54) | 0.729 |
| Medical history, n (%) | | | | |
| Diabetes mellitus | 1 (9) | 5 (6) | 1 (8) | 0.438 |
| Arterial hypertension | 3 (28) | 22 (28) | 4 (31) | 0.667 |
| Smoking | 2 (18) | 15 (20) | 2 (15) | 0.072 |
| Hypercholesterolemia | 3 (27) | 17 (22) | 3 (23) | 0.373 |
| Coronary artery disease | 1 (9) | 3 (4) | 1 (8) | 0.107 |
| Congestive heart failure | 0 (0) | 1 (1) | 1 (8) | 0.078 |
| Atrial septal aneurysm, n (%) | 4 (36) | 26 (34) | 4 (31) | 0.592 |
| Size of shunt by microbubbles | | | | |
| Small, n (%) | 2 (18) | 15 (19) | 2 (15) | 0.631 |
| Moderate, n (%) | 4 (36) | 26 (34) | 5 (38) | 0.187 |
| Large, n (%) | 5 (45) | 36 (47) | 5 (38) | 0.227 |
Follow-up echocardiography showed a continuous decrease of residual shunting during the 6 months following implantation: full closure was present in 179 patients (93%) in Group A and 96 patients (95%) in Group B with no differences between the groups ($p = 0.582$), see Table 3. In cases of persistent residual shunt, the patient was instructed to take aspirin (100 mg daily) long-term. After a mean follow-up of $3.6 \pm 1.2$ years, three recurrent thromboembolic events occurred: one event in Group A (1%) and 2 events in Group B (2%).

### Table 2: Adverse events related to the procedure

| Group A | Amplatzer™ devices (N = 53) | Cardia Ultrasept PFO devices (N = 95) | Occlutech™ devices (N = 44) | p |
|---------|-----------------------------|---------------------------------------|-----------------------------|---|
| Air embolism, n (%) | 0 (0) | 0 (0) | 1 (2) | 0.275 |
| Bleeding, n (%) | 1 (2) | 2 (2) | 0 (0) | 0.099 |
| Cardiac perforation, n (%) | 0 (0) | 0 (0) | 0 (0) | n.s |
| Cardiac thrombosis, n (%) | 0 (0) | 0 (0) | 0 (0) | n.s |
| Deep vein thrombosis, n (%) | 1 (2) | 0 (0) | 0 (0) | 0.172 |
| Device dislocation, n (%) | 0 (0) | 0 (0) | 0 (0) | n.s |
| Infection/sepsis, n (%) | 0 (0) | 1 (1) | 1 (2) | 0.578 |
| Ischemic stroke/TIA, n (%) | 1 (2) | 0 (0) | 0 (0) | 0.199 |
| Pericardial effusion, n (%) | 0 (0) | 0 (0) | 0 (0) | n.s |
| Pulmonary embolism, n (%) | 0 (0) | 0 (0) | 0 (0) | n.s |
| Total, n (%) | 3 (6) | 3 (3) | 2 (5) | 0.536 |

| Group B | Amplatzer™ devices (N = 11) | Cardia Ultrasept PFO devices (N = 77) | Occlutech™ devices (N = 13) | p |
|---------|-----------------------------|---------------------------------------|-----------------------------|---|
| Air embolism, n (%) | 0 (0) | 0 (0) | 0 (0) | n.s |
| Bleeding, n (%) | 0 (0) | 1 (2) | 0 (0) | 0.711 |
| Cardiac perforation, n (%) | 0 (0) | 0 (0) | 0 (0) | n.s |
| Cardiac thrombosis, n (%) | 0 (0) | 0 (0) | 0 (0) | n.s |
| Deep vein thrombosis, n (%) | 0 (0) | 0 (0) | 1 (7) | 0.037 |
| Device dislocation, n (%) | 0 (0) | 0 (0) | 0 (0) | n.s |
| Infection/sepsis, n (%) | 0 (0) | 1 (3) | 0 (0) | n.s |
| Ischemic stroke/TIA, n (%) | 0 (0) | 0 (0) | 0 (0) | n.s |
| Pericardial effusion, n (%) | 0 (0) | 0 (0) | 0 (0) | n.s |
| Pulmonary embolism, n (%) | 0 (0) | 0 (0) | 0 (0) | n.s |
| Total, n (%) | 1 (9) | 3 (4) | 1 (7) | 0.074 |

### Table 3: Events during follow-up

| Group A | Amplatzer™ devices (N = 53) | Cardia Ultrasept PFO devices (N = 95) | Occlutech™ devices (N = 44) | p |
|---------|-----------------------------|---------------------------------------|-----------------------------|---|
| Recurrent ischemic stroke/TIA, n (%) | 1 (2) | 0 (0) | 0 (0) | 0.832 |
| Cardiac death, n (%) | 0 (0) | 0 (0) | 0 (0) | n.s. |
| Device related thrombosis, n (%) | 0 (0) | 0 (0) | 0 (0) | n.s. |
| New onset of atrial fibrillation, n (%) | 3 (6) | 1 (1) | 3 (7) | 0.043 |
| Residual shunt, n (%) | 4 (8) | 6 (6) | 3 (7) | 0.216 |

| Group B | Amplatzer™ devices (N = 11) | Cardia Ultrasept PFO devices (N = 77) | Occlutech™ devices (N = 13) | p |
|---------|-----------------------------|---------------------------------------|-----------------------------|---|
| Recurrent ischemic stroke/TIA, n (%) | 1 (9) | 0 (0) | 1 (8) | 0.002 |
| Cardiac death, n (%) | 0 (0) | 0 (0) | 0 (0) | n.s. |
| Device related thrombosis, n (%) | 0 (0) | 0 (0) | 0 (0) | n.s. |
| New onset of atrial fibrillation, n (%) | 2 (18) | 1 (1) | 1 (8) | 0.032 |
| Residual shunt, n (%) | 1 (9) | 3 (4) | 1 (8) | 0.393 |
with no significant differences in both groups (p = 0.112). Additionally, we saw new onset of atrial fibrillation in 7 patients in Group A and in 4 patients in Group B. Notably, there were no differences between the groups (p = 0.662). If we look at the final results of both groups we find that there are no significant differences in the event rate in both main groups and subgroups (Table 3).

4 | DISCUSSION

In our dual-center experience, we highlight that interventional PFO closure could be conducted safely in patients both under and over 60 years of age, significantly reducing the recurrence of stroke in both populations equally. The generally accepted recommendation that patients over 60 years old should be denied treatment in the form of an interventional PFO closure should be reconsidered, especially when taking into account the aging demographics of the world’s population.

The results of our study underscore that age alone should not be a primary exclusionary factor when deciding whether an interventional treatment is suitable for a patient with PFO. Physicians are instead advised to take further criteria, such as, medical history and general health, into consideration on a case-by-case basis when determining the best course of action for each individual. In all device types, PFO occlusion was found to be safe and effective in patients over 60 years of age compared with patients under 60.

Our study has a few limitations, specifically that it is a small non-randomized observational study. Furthermore, follow-ups were performed by TEE examinations after 3 and 6 months and through telephone contact with the patient and the practitioner regarding cardiovascular or neurological events. However, there may be a recall bias and an opportunity to miss or to over-interpret clinical events.

5 | CONCLUSION

In cases of patent foramen ovale following cryptogenic ischemic stroke, patients over 60 years of age could also be considered suitable candidates to receive interventional closure of the PFO in order to substantially reduce the risk of a recurrent stroke, and age alone should not be considered a limiting factor. Based on the results of this study, interventional closure of patent foramen ovale could be as safe and effective in patients over 60 years of age as it is in patients under 60 years of age. In order to determine the best treatment options, the patient’s cardiologist and neurologist are tasked with deciding on the optimal course of action based on the individual patient’s medical history and current physical condition. Since it is linked to the increasing life expectancy and improved quality of life of the population, this topic will occupy us doctors more in the future. For this purpose, in order to make a strong definitive statement, we need multi-center randomized large studies.

CONFLICT OF INTEREST

The authors declare no potential conflict of interest.

DATA AVAILABILITY

All data are available at the Rhein-Maas Hospital, covered by Prof. Michael Becker.

ORCID

Michael Becker https://orcid.org/0000-0001-6200-6465

REFERENCES

1. Sacco RL, Ellenberg JH, Mohr JP, et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol. 1989;25(4):382-390. https://doi.org/10.1002/ana.410250410.
2. Li L, Yin GS, Geraghty OC, et al. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. Lancet. 2015;14 (9):903-913. https://doi.org/10.1016/s1474-4422(15)00132-5.
3. Calvert PA, Rana BS, Kydd AC, Shapiro LM. Patent foramen ovale: anatomy, outcomes, and closure. Nat Rev Cardiol. 2011;8(3):148-160. https://doi.org/10.1038/nrccardio.2010.224.
4. Di Tullio M, Sacco RL, Gopal A, Mohr JP, Homma S. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med. 1992;117(6):461-465. https://doi.org/10.7326/0003-4819-117-6-461-465.
5. Meissner I, Khandheria BK, Heit JA, et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am College Cardiol. 2006;47(2):440-445. https://doi.org/10.1016/j.jacc.2005.10.044.
6. Petty GW, Khandheria BK, Meissner I, et al. Population-based study of the relationship between patent foramen ovale and cerebrovascular ischemic events. Mayo Clin Proc. 2006;81(5):602-608. https://doi. org/10.4065/81.5.602.
7. Li J, Liu J, Liu M, et al. Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack. Cochrane Database Syst Rev. 2015;(9):Cd009938. https://doi.org/10.1002/14651858.CD009938.pub2.
8. Spencer FA, Lopes LC, Kennedy SA, Guyatt G. Systematic review of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale. BMJ Open. 2014;4(3): e004282. https://doi.org/10.1136/bmjopen-2013-004282.
9. Khan AR, Bin Abdulhak AA, Sheikh MA, et al. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis. JACC Cardiovasc Interv. 2013;6(12): 1316-1323. https://doi.org/10.1016/j.jcin.2013.08.001.
10. Kent DM, Dahabreh IJ, Ruthazer R, et al. Device closure of patent foramen ovale after stroke: pooled analysis of completed randomized trials. J Am Coll Cardiol. 2016;67(8):907-917. https://doi.org/10.1016/j.jacc.2015.12.023.
11. Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial. J Am Coll Cardiol. 2018;71(20):2335-2342. https://doi.org/10.1016/j.jacc.2018.02.046.
12. Sondergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377(11):1033-1042. https://doi.org/10.1056/NEJMoa1707404.
13. Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or antiaggregation vs. antiplatelets after stroke. N Engl J Med. 2017;377(11):1011-1021. https://doi.org/10.1056/NEJMoa1705915.
14. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377(11):1022-1032. https://doi.org/10.1056/NEJMoa1610057.
15. Alsheikh-Alli AA, Thaler DE, Kent DM. Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke. 2009;40(7):2349-2355. https://doi.org/10.1161/strokeaha.109.547828.
16. Hart RG, Diener HC, Coutts SB, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429-438. https://doi.org/10.1016/s1474-4422(13)70310-7.

17. Srivastava TN, Payment MF. Images in clinical medicine. Paradoxical embolism—thrombus in transit through a patent foramen ovale. N Engl J Med. 1997;337(10):681. https://doi.org/10.1056/nejm199709043371005

18. Messe SR, Gronseth G, Kent DM, et al. Practice advisory: recurrent stroke with patent foramen ovale (update of practice parameter): Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016;87(8):815-821. https://doi.org/10.1212/wnl.0000000000002961.

19. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology. 2000;55(8):1172-1179. https://doi.org/10.1212/wnl.55.8.1172.

20. Jones EF, Calafiore P, Donnan GA, Tonkin AM. Evidence that patent foramen ovale is not a risk factor for cerebral ischemia in the elderly. Am J Cardiol. 1994;74(6):596-599. https://doi.org/10.1016/0002-9149(94)90750-1.

21. Yeung M, Khan KA, Shuaib A. Transcranial Doppler ultrasonography in the detection of venous to arterial shunting in acute stroke and transient ischaemic attacks. J Neurol Neurosurg Psychiatry. 1996;61(5):445-449. https://doi.org/10.1136/jnnp.61.5.445.

22. Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357(22):2262-2268. https://doi.org/10.1056/NEJMoa071422.